Search results for "Replacement"

showing 10 items of 561 documents

Mental health perspectives of Hunter syndrome: Case reports of two biological siblings

2016

Hunter syndrome is a rare X-linked recessive disorder caused by deficiency of the lysosomal enzyme iduronate-2-sulphatase, leading to progressive accumulation of a substance called glycosaminoglycans in nearly all cell types, tissues, and organs. Hunter syndrome presents with facial dysmorphism, airway diseases, skeletal defects, cardiomyopathies, and neuropsychiatric manifestations. Mental subnormality is a cardinal feature in Hunter syndrome. This is a progressive cognitive decline that is not amenable to enzyme replacement therapy. Due to progressive cognitive decline, training the children to improve the adaptive functioning is a challenge that creates immense stress for the caregivers.…

Pediatricsmedicine.medical_specialtybusiness.industrylcsh:Reducationlcsh:MedicineHunter syndromeGeneral MedicineEnzyme replacement therapycognitive declinemedicine.diseaseMental healthProgressive cognitive declineBiological siblingsAdaptive functioningFacial dysmorphismHunter syndromeMedicineCognitive declinebusinessMental subnormalityMedical Journal of Dr. D.Y. Patil University
researchProduct

Effect of hormone replacement therapy (HRT) on periodontal status of postmenopausal women.

2011

Summary Background The risks/benefits balance of hormone replacement therapy (HRT) is controversial. The aim of this study was to assess the periodontal status of a postmenopausal women group receiving HRT and to determine the effects of HRT on clinical measures of periodontal disease. Material/Methods Ninety-one postmenopausal women, 52 taking HRT (HRT+) and 39 not taking HRT (HRT−), completed the study. Clinical parameters measured included visible supragingival plaque, probing pocket depth (PD) and clinical attachment level (CAL). Gingival status was recorded as gingival bleeding on probing (BOP). Previous oral contraceptive use and current and past smoking status were also assessed. Res…

Periodontiummedicine.medical_specialtygenetic structuresPeriodontal diseaseSettore MED/28 - Malattie OdontostomatologicheInternal medicineMedicineHumansEstrogen replacement therapyperiodontitisGynecologyPostmenopausal womenbusiness.industryEstrogen Replacement TherapyGeneral MedicineMiddle Agedeye diseaseshormone replacement therapypostmenopausefemaleTransgender hormone therapyhormone replacement therapy (HRT) postmenopause chronic periodontitis gingivitis femalesense organsPublic HealthbusinessgingivitisMedical science monitor : international medical journal of experimental and clinical research
researchProduct

<p>Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis</p>

2019

Purpose Following the publication of 5-year agalsidase alfa enzyme replacement therapy (ERT) outcomes data from the Fabry Outcome Survey (FOS), 10-year data were analyzed. Patients and methods FOS (ClinicalTrials.gov identifier: NCT03289065) data (April 2001 to August 2018) were retrospectively analyzed. Estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) were analyzed after treatment start (baseline) for patients with ≥3 measurements, including baseline and year 10. Results Median (range) age (years) of the evaluable treated renal cohort at treatment start was 48.8 (17.9-67.3) for females (n=62), 34.4 (18.0-66.8) for males (n=90). With eGFR ≥60 mL…

Pharmacologymedicine.medical_specialtyAlpha-galactosidasebiology030232 urology & nephrologyUrologyPharmaceutical ScienceRenal functionRetrospective cohort studyEnzyme replacement therapy030204 cardiovascular system & hematologymedicine.diseaseFabry disease03 medical and health sciences0302 clinical medicineDrug DiscoveryCohortmedicinebiology.proteinYoung adultCohort studyDrug Design, Development and Therapy
researchProduct

mRNA-based therapeutics — developing a new class of drugs

2014

In vitro transcribed (IVT) mRNA has recently come into focus as a potential new drug class to deliver genetic information. Such synthetic mRNA can be engineered to transiently express proteins by structurally resembling natural mRNA. Advances in addressing the inherent challenges of this drug class, particularly related to controlling the translational efficacy and immunogenicity of the IVTmRNA, provide the basis for a broad range of potential applications. mRNA-based cancer immunotherapies and infectious disease vaccines have entered clinical development. Meanwhile, emerging novel approaches include in vivo delivery of IVT mRNA to replace or supplement proteins, IVT mRNA-based generation o…

Pluripotent Stem CellsPharmacologyDrugImmunogenicitymedia_common.quotation_subjectProteinsGeneral MedicineComputational biologyBiologyPharmacologyGenome engineeringDrug Delivery SystemsDrug classProtein replacement therapyDrug developmentInfectious disease (medical specialty)Drug DesignDrug DiscoveryAnimalsHumansImmunotherapyRNA MessengerInduced pluripotent stem cellmedia_commonNature Reviews Drug Discovery
researchProduct

Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group

2011

Import JabRef | WosArea Orthopedics; Rheumatology; International audience; Objective: The Osteoarthritis Research Society International initiated a number of working groups to address a call from the US Food and Drug Administration (FDA) on updating draft guidance on conduct of osteoarthritis (OA) clinical trials. The development of disease-modifying osteoarthritis drugs (DMOADs) remains challenging. The Assessment of Structural Change (ASC) Working Group aimed to provide a state-of-the-art critical update on imaging tools for OA clinical trials. Methods: The Group focussed on the performance metrics of conventional radiographs (CR) and magnetic resonance imaging (MRI), performing systemati…

Predictive validityCartilage Articularmedicine.medical_specialtyBiomedical EngineeringOsteoarthritisKNEE OSTEOARTHRITISRADIOGRAPHIC PROGRESSIONArticleValidityCARTILAGE LOSSMagnetic resonance imagingRheumatologyMARKERSSynovitisOsteoarthritismedicineHumansOrthopedics and Sports MedicineArthrographyReliability (statistics)Conventional radiographyREPLACEMENT SURGERYModalitiesmedicine.diagnostic_testbusiness.industryJOINTAnti-Inflammatory Agents Non-Steroidal[SCCO.NEUR] Cognitive science/NeuroscienceReproducibility of ResultsMagnetic resonance imagingResponsivenessmedicine.diseaseReliabilityClinical trialTreatment OutcomeTRIALS[ SCCO.NEUR ] Cognitive science/NeurosciencePhysical therapyJointsMetric (unit)business
researchProduct

Comparative evaluation of three semi-quantitative radiographic grading techniques for knee osteoarthritis in terms of validity and reproducibility in…

2008

OBJECTIVE: The objective of this work was to compare the measurement properties of three categorical X-ray scoring methods of knee osteoarthritis (OA), both on semiflexed and extended views. METHODS: In data obtained from trials and cohorts, X-rays were graded using Kellgren and Lawrence (KL), the OA Research Society International (OARSI) joint space narrowing score, and measurement of joint space width (JSW). JSW was analyzed as a categorical variable. Construct validity was assessed through logistic regression between X-ray stages and Western Ontario and McMaster Universities OA Index. Inter-observer reliability was assessed in 50 subjects for extended views by weighted kappa. Intra-obser…

Predictive validitymedicine.medical_specialtyDatabases FactualKnee JointPsychometricsJoint replacementmedicine.medical_treatmentBiomedical EngineeringLogistic regressionSeverity of Illness IndexValidity03 medical and health sciences0302 clinical medicineRheumatologyOsteoarthritismedicineHumansOrthopedics and Sports MedicineKneeCategorical variableObserver Variation030203 arthritis & rheumatology030222 orthopedicsProgressionbusiness.industryReproducibility of ResultsConstruct validityIntra-rater reliabilityOsteoarthritis KneeReproducibilityRadiographyInter-rater reliabilityDisease ProgressionPhysical therapybusinessKappa
researchProduct

Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease

2009

Pregnancymedicine.medical_specialtybusiness.industryTreatment outcomeMEDLINEObstetrics and GynecologyEnzyme replacement therapymedicine.diseaseFabry diseaseReproductive MedicineInternal medicinemedicinebusinessAgalsidase alfaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Crystal structure of bacteriophage fr capsids at 3.5 A resolution.

1994

The structure of recombinant capsids of the bacterial virus fr has been determined by X-ray crystallography at 3.5 A resolution. The capsids were produced by expressing the fr coat protein in Escherichia coli, the natural host of the virus, and are probably essentially identical to the protein shell of the native virus. The structure was determined using molecular replacement with the protein shell of the related MS2 virus, and refined to a crystallographic R-factor of 0.228. A comparison of the protein shells of the viruses shows that they are very similar, and indicates that they may have a similar regulation of the assembly of the quasi-symmetrical protein shell.

Protein ConformationvirusesMolecular Sequence DataRNA PhagesBiologymedicine.disease_causeCrystallography X-RayViruslaw.inventionBacteriophageCapsidStructural BiologylawmedicineComputer GraphicsEscherichia coliMolecular replacementAmino Acid SequenceMolecular BiologyEscherichia coliConserved SequenceLevivirusResolution (electron density)biology.organism_classificationRecombinant ProteinsCrystallographyCapsidMutationBiophysicsRecombinant DNABacterial virusSequence AlignmentJournal of molecular biology
researchProduct

Outcome after mitral valve operations with depressed left ventricular function.

2012

We retrospectively investigated 42 patients (27 men, 15 women; mean age, 67 years) with severe mitral valve incompetence and endstage cardiomyopathy (ejection fraction <30%) who were operated on between January 2002 and March 2009. Of these, 14 were in New York Heart Association class IV, and 27 were in class III. The etiology was ischemic in 18 patients and idiopathic dilated in 24. Mitral valve repair was performed in 25 patients, and 17 had mitral valve replacement. The mean logistic EuroSCORE was 33.41. The mean follow-up was 44.52 months. There were no perioperative deaths. Three patients died within 30 days postoperatively. Thirty-day mortality was lower than predicted by EuroSCOR…

Pulmonary and Respiratory MedicineAdultMaleReoperationmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCardiomyopathyKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexVentricular Function LeftVentricular Dysfunction LeftRisk FactorsInternal medicineMitral valveGermanymedicineHumansCardiac Surgical ProceduresSurvival rateAgedProportional Hazards ModelsRetrospective StudiesAged 80 and overHeart Valve Prosthesis ImplantationMitral valve repairEjection fractionbusiness.industryMitral valve replacementMitral Valve InsufficiencyEuroSCOREStroke VolumeGeneral MedicinePerioperativeMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureLogistic ModelsTreatment OutcomeMultivariate AnalysisCardiologyMitral ValveSurgeryFemaleCardiology and Cardiovascular MedicinebusinessCardiomyopathiesAsian cardiovascularthoracic annals
researchProduct

Feasibility of transcatheter aortic valve implantation in patients with coronary heights ≤7 mm: insights from the transcatheter aortic valve implanta…

2018

OBJECTIVES Transcatheter aortic valve implantation (TAVI) in patients with low coronary heights is generally denied but is not impossible. Information about these high-risk procedures is sparse. METHODS Since May 2008, data of more than 3000 patients who had TAVI were prospectively collected in the institutional TAVI Karlsruhe registry. Characteristics, peri- and postoperative outcome of patients with low coronary heights of ≤7 mm were analysed according to the Valve Academic Research Consortium-2. RESULTS Eighty-six patients with an average coronary height of 6.4 ± 1.1 mm (mean age 81.0 ± 5.3 years, logistic EuroSCORE I 19.6 ± 13.3%) were treated. TAVI was performed in 72 transfemoral (83.…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicinePostoperative ComplicationsValve replacementGermanyMedicineHumans030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyAortic dissectionAged 80 and overBioprosthesisbusiness.industryMortality rateIncidenceHazard ratioExtracorporeal circulationPercutaneous coronary interventionGeneral MedicineAortic Valve Stenosismedicine.diseaseCoronary VesselsSurgerySurvival RateTreatment OutcomeCoronary OcclusionCoronary occlusionAortic ValveFluoroscopyFeasibility StudiesSurgeryFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct